Last reviewed · How we verify
anti-TL1A monoclonal antibody, low dose
anti-TL1A monoclonal antibody, low dose is a Biologic drug developed by Biocad. It is currently in Phase 2 development.
At a glance
| Generic name | anti-TL1A monoclonal antibody, low dose |
|---|---|
| Sponsor | Biocad |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis (PHASE2)
- Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-TL1A monoclonal antibody, low dose CI brief — competitive landscape report
- anti-TL1A monoclonal antibody, low dose updates RSS · CI watch RSS
- Biocad portfolio CI
Frequently asked questions about anti-TL1A monoclonal antibody, low dose
What is anti-TL1A monoclonal antibody, low dose?
anti-TL1A monoclonal antibody, low dose is a Biologic drug developed by Biocad.
Who makes anti-TL1A monoclonal antibody, low dose?
anti-TL1A monoclonal antibody, low dose is developed by Biocad (see full Biocad pipeline at /company/biocad).
What development phase is anti-TL1A monoclonal antibody, low dose in?
anti-TL1A monoclonal antibody, low dose is in Phase 2.